Table 1.

Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the CHNRI process

Reference	MV Strain	Age group	Seroconversion as defined by authors
A.Dilraj et al [46]	MV-Schwarz ( s/c, aerosol), MV- Edmonston-Zagreb ( s/c, aerosol)	992 participants 5-14 years	Seroconversion rates (defined as four fold increase in antibody level): EZ Aerosol – 84.7% EZ sc – 78.8% SW Aerosol – 22.7% SW sc – 62.6%
A.Dilraj et al [47]	MV-Schwarz ( s/c), MV- Edmonston-Zagreb ( s/c, aerosol)	337 participants 5-14 years	Seroconversion (defined as four fold increase in antibody level) at 6 years after revaccination: EZ Aerosol – 86% EZ sc – 73% SW sc – 58%
J.A.Bellanti et al [48]	MV- Edmonston-Zagreb ( s/c, aerosol)	49 participants 6-7 years	The mean Specific anti-measles IgG antibody: EZ sc - 22.9 ± 4.6 EZ aerosol - 53.4 ± 9.4 Results are reported as mean _ µg/ml ± standard error of the mean
J.V.Bennett et al [49]	MV-Schwarz ( s/c), MV- Edmonston-Zagreb ( s/c, aerosol)	1624 participants 6-8 years	Change from seronegative to seropositive, >= 120 mIU/ml EZ aerosol – 65% EZ sc – 4% SW sc – 23%
R.M.Wong-Chew et al [50]	MV- Edmonston-Zagreb ( s/c, aerosol)	114 participants 11-13 months	Seroresponse rates as defined by four fold increase in antibody level: EZ aerosol – 89.8% EZ sc – 100%
R.M.Wong-Chew et al [51]	MV- Edmonston-Zagreb ( s/c, aerosol)	129 participants 8-10 months	Seroresponse rates as defined by four fold increase in antibody level: EZ Aerosol – 42% EZ sc – 67%